MiMedx Group
Stock Forecast, Prediction & Price Target
MiMedx Group (MDXG) stock Price Target by analysts
$16
Potential upside: 125.35%
MiMedx Group price prediction
What is MiMedx Group stock analysts` prediction?
MiMedx Group stock forecast: Based on 1 Wall Street analysts` predicted price targets for MiMedx Group in the last 3 months, the avarage price target is $16, with a high forecast of $NaN. The average price target represents a 125.35% change from the last price of $7.1.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
MiMedx Group stock Price Target by analysts
Full breakdown of analysts given MiMedx Group price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Anthony Petrone Mizuho Securities | 0% 0/1 | 10 months ago | $16 125.35% upside | $9.09 | StreetInsider | Previous targets (0) |
Ross Osborn Cantor Fitzgerald | 0% 0/1 | about 1 year ago | $11 54.92% upside | $6.7 | TheFly | Previous targets (0) |
Brooks O’Neil Lake Street | 0% 0/1 | over 1 year ago | $12 69.01% upside | $6.27 | TheFly | Previous targets (0) |
Unknown H.C. Wainwright | N/A | almost 3 years ago | $8 12.67% upside | $3.42 | Benzinga | N/A |
MiMedx Group Financial Estimates
MiMedx Group Revenue Estimates
MiMedx Group EBITDA Estimates
MiMedx Group Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $258.61M N/A | $267.84M 3.56% | $321.47M 20.02% | Avg: $406.16M Low: $396.83M High: $422.46M avg. 26.34% | Avg: $477.93M Low: $468.79M High: $491.04M avg. 17.66% | Avg: $487.02M Low: $477.70M High: $500.38M avg. 1.90% | Avg: $553.89M Low: $543.29M High: $569.09M avg. 13.73% |
Net Income
% change YoY
| $-10.28M N/A | $-30.19M -193.60% | $67.43M 323.33% | Avg: $55.79M Low: $48.16M High: $91.95M avg. -17.26% | Avg: $72.98M Low: $64.22M High: $151.80M avg. 30.81% | Avg: $96.33M Low: $93.93M High: $99.77M avg. 31.98% | Avg: $131.36M Low: $128.10M High: $136.05M avg. 36.36% |
EBITDA
% change YoY
| $178K N/A | $-20.92M -11857.86% | $40.51M 293.59% | Avg: $-11.77M Low: $-12.24M High: $-11.50M avg. -129.06% | Avg: $-13.85M Low: $-14.23M High: $-13.58M avg. -17.66% | Avg: $-14.11M Low: $-14.50M High: $-13.84M avg. -1.90% | Avg: $-16.05M Low: $-16.49M High: $-15.74M avg. -13.73% |
EPS
% change YoY
| -$0.09 N/A | -$0.27 -189.69% | $0.48 277.77% | Avg: $0.42 Low: $0.33 High: $0.63 avg. -13.54% | Avg: $0.67 Low: $0.44 High: $1.04 avg. 61.44% | Avg: $0.66 Low: $0.64 High: $0.68 avg. -1.49% | Avg: $0.9 Low: $0.88 High: $0.93 avg. 36.36% |
Operating Expenses
% change YoY
| $220.31M N/A | $244.49M 10.97% | $229.72M -6.04% | Avg: $292.02M Low: $285.30M High: $303.74M avg. 27.11% | Avg: $343.61M Low: $337.04M High: $353.04M avg. 17.66% | Avg: $350.15M Low: $343.45M High: $359.75M avg. 1.90% | Avg: $398.22M Low: $390.61M High: $409.15M avg. 13.73% |
FAQ
What is MiMedx Group stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.47% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is 48.16M, average is 55.79M and high is 91.95M.
What is MiMedx Group stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 14.91% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $396.83M, average is $406.16M and high is $422.46M.
What is MiMedx Group stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 20.69% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is $0.33, average is $0.42 and high is $0.63.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering MiMedx Group stock. The most successful analyst is Anthony Petrone.